What we are studying
The purpose of this research study is to compare the effects (good and bad) of pembrolizumab given every three weeks with or without low dose carboplatin and paclitaxel. The drug pembrolizumab is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells. Pembrolizumab had been approved for the treatment of melanomas and is being studied for the treatment of patients with Non-Small Cell Lung Cancer . Carboplatin and paclitaxel are chemotherapy drugs approved by the US Food and Drug Administration (FDA) for treatment of your disease. The goal of this study is to determine if carboplatin and paclitaxel can improve the anti-tumor activity of pembrolizumab.